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Abstract
In humans, the role and relationship between molecular pathways that lead to tissue destruction during acute
allograft rejection are not fully understood. Based on studies conducted in humans, we recently hypothesized that
different immune-mediated tissue destruction processes (i.e. cancer, infection, autoimmunity) share common
convergent final mechanisms. We called this phenomenon the “Immunologic Constant of Rejection (ICR).” The
elements of the ICR include molecular pathways that are consistently described through different immune-
mediated tissue destruction processes and demonstrate the activation of interferon-stimulated genes (ISGs), the
recruitment of cytotoxic immune cells (primarily through CXCR3/CCR5 ligand pathways), and the activation of
immune effector function genes (IEF genes; granzymes A/B, perforin, etc.).
Here, we challenge the ICR hypothesis by using a meta-analytical approach and systematically reviewing microarray
studies evaluating gene expression on tissue biopsies during acute allograft rejection. We found the pillars of the
ICR consistently present among the studies reviewed, despite implicit heterogeneity.
Additionally, we provide a descriptive mechanistic overview of acute allograft rejection by describing those
molecular pathways most frequently encountered and thereby thought to be most significant. The biological role
of the following molecular pathways is described: IFN-g, CXCR3/CCR5 ligand, IEF genes, TNF-a, IL-10, IRF-1/STAT-1,
and complement pathways. The role of NK cell, B cell and T-regulatory cell signatures are also addressed.
Introduction
Defining the interplay between molecular pathways
within highly complex biological systems, such as those
between immune cell networks and target tissues, is cer-
tainly a daunting task. The advent of high-throughput
gene expression technology has served as an extremely
useful tool to enable investigators to characterize biolo-
gical events taking place within humans, reducing the
inherent bias often generated by testing specific but
restricted hypotheses derived from animal models. Pre-
viously, we applied this approach to profiling tumor
lesions in humans, before and after immunotherapy, to
identify molecular pathways activated during immune-
mediated tumor rejection. These pathways illustrate a
process characterized by the coordinated activation of
interferon stimulated genes (ISGs), the recruitment of
cytotoxic cells through the massive production of speci-
fic chemokine ligands, and the activation of immune
effector function (IEF) genes (genes expressed by NK
cells and CD8 T cells upon activation) [1-4]. Similar
pathways have been described among other immune-
mediated tissue destruction processes such as those
occurring during autoimmunity, graft versus host dis-
ease (GVHD), infection clearance, acute cardiovascular
events, chronic obstructive pulmonary disease, and pla-
cental villitis [5-10]. These observations suggest that
these distinct tissue destruction processes share com-
mon final immune-mediated molecular mechanisms.
We termed this phenomenon as the “Immunologic
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stants shared among these different tissue destruction
processes include the coordinated activation of the fol-
lowing pathways: I) STAT-1/IRF-1/T-bet/IFN-g/IL-15
pathway; II) CXCR3 ligand chemokine pathway
(CXCL9, -10, -11) III) CCR5 ligand chemokine pathway
(CCL3, -4, -5) and IV) TIA-1 pathway/granzyme A/B/
granulysin/perforin pathway [3,4].
Over the past decade gene expression microarrays
have been employed to study allograft rejection in
humans. The intrinsic heterogeneity among different
investigators in terms of patient selection, microarray
platforms, gene coverage, statistical analysis, sample col-
lection and study design makes cross-comparison
between different studies very challenging. Furthermore,
since microarray profiling is a relatively new technology,
it has continued to evolve in sophistication and has only
recently become standardized [11,12]. For this reason
w eb e l i e v et h a td e s p i t et h en o n - u n i f o r m i t ya m o n gs t u -
dies, genes that are consistently reported across different
studies and in different organs command attention. In
this review we challenge the concept of the ICR by
examining multiple studies to evaluate the presence of
the “constants of rejection.” We tested the ICR hypoth-
esis by describing the most frequently reported immune
pathways activated during acute allograft rejection in
humans as reported by publications using microarray
technologies. Biological explanations for relevant path-
ways are provided based on pertinent literature.
Data Extraction Criteria
In this review we focused on high-throughput gene
expression profiling studies which sought to characterize
the molecular features of acute allograft rejection.
Accordingly, we searched various combinations of the
following MeSH terms/keywords in PubMed: “gene
expression, ““ acute, ““ allograft, ““ rejection, “ and
“microarray.” Searches were performed independently by
two investigators. Gene Expression Omnibus (GEO) and
reference lists of original articles and review articles also
served as additional search methods. Microarray studies
providing original data and performed on human tissue
biopsies during established acute allograft rejection were
selected and evaluated [13-46]). Studies analyzing gene
expression profiles of peripheral blood mononuclear
cells and urine sediments during acute rejection will not
be considered here, despite their potential utility as non-
invasive diagnostic/predictive tools [47-51].
The compiled list of key genes in this review came
from those reported as upregulated in the original publi-
cations, most of which were predominantly immune-
related and are reported in Table 1. In total, 15 unique
datasets met the search criteria, and comprise Tables 1
and 2. Of these datasets, four comparative analyses were
among those selected for inclusion. Of note, all of the
studies contained original data from de novo
investigation.
The Ingenuity Systems Pathway Analysis (IPA) http://
www.ingenuity.com and MetaCore http://www.genego.
com were used to illustrate the relationships among the
compiled list of key genes. Additional detail regarding
the data extraction is provided in Additional File 1.
Overview of microarray studies
Considering the heterogeneity among the selected stu-
dies in terms of platform used, purpose, design, and
interpretation (see also Table 2), a quantitative approach
was not feasible, making this review qualitative in nat-
ure. The diversity of the clinical setting (pediatric or
adult patients; heart, lung, liver or kidney transplants)
also added complexity to this analysis. The purposes of
the original studies included here ranged between class
discovery, class comparison, and/or class prediction. Dif-
ferent methods (summarized in Table 2) were used by
different investigators to provide a list of genes modu-
lated during acute allograft rejection. Not surprisingly,
little overlap exists among studies with respect to speci-
fic ‘genes’ described as upregulated during acute rejec-
tion, yet, we found a striking consistency in terms of
pathway overrepresentation suggesting that each indivi-
dual study identified different pieces of the same puzzle.
It should be noted that these studies lacked the use of
micro/macro-dissection which prohibited identification
of the cellular source of the transcripts differentially
expressed during acute rejection. It is logical to think
that analysis of RNA from the whole tissue samples
could influence gene expression patterns. With this in
mind, Sarwal et al. [22], investigated if the molecular
changes observed during allograft rejection could have
been related to the differential sampling of cortical and
medullary kidney sections. For this analysis the authors
excluded the genes whose expression was shown to be
correlated with the depth of biopsy in a previous investi-
gation. The introduction of this filter did not signifi-
c a n t l yc h a n g et h er e s u l t s .I nanother study involving
kidney recipients, Rodder et al. [29] performed qRT-
PCR on isolated glomeruli, and on proximal and distal
tubules. Although qRT-PCR of targets genes (metzincins
and related genes) revealed some differences between
glomeruli and tubules, it confirmed, overall, the differ-
ences between acute rejection and normal samples
detected by microarray analysis.
The Immunologic Constant of Rejection pathways in
acute allograft rejection
After reviewing the literature, we found that pathways
involved in the ICR hypothesis are frequently activated
during acute allograft rejection across studies conducted
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Page 2 of 22Table 1 Key genes associated with acute allograft rejection according to human microarray studies
Author: Tannapfel et al. 2001 [14]
Organ: Liver
IL3 MMP9 TGF-B1-3 TIMP1 TNF CLUSTERIN
(CLU)
IL10
Author: Sreekumar et al. 2002 [15]
Organ: Liver
C1QB C3 LIPC GZMB HSPA1A IGF1 IL2 (IRF9*) STAT1 ACADM
HLA-I HLA-II PCK1 SELPLG TGFB1 TNF TNFAIP3 TNFSF10 UBB
3# UBA1
UBE2N ADAM17 GYS2 CTPS
Inkinen et al. 2005 [16]
Organ: Liver
HLA-D IL2RB IL2RG CASP1 CASP3 GZMA GZMB SELL ICAM3 ITGA4
SELE VCAM1 IFNG IL1B
Asaoka et al. 2009 [28]
Organ: Liver
AKAP11 ALOX15 CASP8 CFLAR FFAR3 IFNAR1 IGFBP3 IL12RB1 LTA POU4F1
PPP1R8 PPP1R3A PVRL1 TNK2
Author: Gimino et al. 2003 [17]Lande et al. 2006 [30](MINNEAPOLIS Dataset)
Organ: Lung
C4B CCR7 CD28 CD3E CD84 CTLA4 CXCR3 GZMK GZMA IFNG
IGKC ITK KIR PRF1 STAT4 IL2RA IL2RB Zap70 LCK
Patil et al. 2008 (MINNEAPOLIS2 Dataset) [18]
Organ: Lung
IFITM1 CD8A MARCKS CCL3 GZMB ITM2A IL32 IL8 CCL4
Author: Karason et al. 2006 [19]
Organ: Heart
C3 C4A CXCL9 CXCL10 GBP1 HLA-C HLA-F HLA-J IGFBP4 NPPA
PSME2 RARRES3 STAT1
Author: Akalin et al. 2001 [21]
Organ: Kidney
Humig
(CXCL9)
C3 CD18
(ITGB2)
ISGF-3
(STAT1)
MCL1 MIP-3b
(CCL19)
NNMT RING4
(TAP1)
TCRB
# IL2-SP
2#
(LCP1)
Author: Sarwal et al. 2003 (STANFORD Dataset) [22]
Organ: Kidney
HLA-A HLA-B HLA-C HLA-E HLA-DR HLA-DQ HLA-DMA HLA-DRB4 TGFBR2 TGFR1
TCR DARC C4B CXCL9 SCYA3
(CCL3)
SCYA5
(CCL5)
CCR5 SCYA2
(CCL2)
CD20 PERFORIN
CD53 NFKB1 NK4
(IL32)
CX3CR1 GZMA STK17B IL6R IL2RB IL15RA IL16
STAT1 CASP10 IFNGR1 IGHG3 IGKC IGL IGHM LENG4 CD59 VCAM1
CXCL9 CXCL10 CCR5
Author: Flechner et al. 2004 (CLEVELAND Dataset) [23]
Organ: Kidney
C1QB CCL5 CD14 CD163 TRB@ CD16 CD2 CD27 CD3D CD48
CD53 CD64
(FCGR1A)
CD8 CDW52 CXCR4 GZMA HLA-F IFI30 IL10RA IL10RB
IL4R ISG20 PKR
(PRKRA)
RAGE4
(RAGE)
TNFRSF1b
Reeve et al. 2009 (EDMONTON Dataset) [24]
Organ: Kidney
APOBEC3G CCL4 CCL5 CD8A CRTAM CXCL9 CXCL10 CXCL11 FAM26F GBP1
GBP2 GBP4 GBP5 GZMA GZMB INDO LCP2 LILRB1 NLRC5 PSMB9
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Page 3 of 22Table 1 Key genes associated with acute allograft rejection according to human microarray studies (Continued)
Author: Morgun et al. 2006 (SAN PAULO Dataset) [25]
Organ: Heart + Lung + Kidney
(SAN PAULO+ MINNEAPOLIS+STANFORD+CLEVELAND Datasets)
ABCA7 CD14 DAP10 HLA-A HSD17B7 ISG20 LEF1 NT5C2 RU2 TRAF2
ADAM15 CD2 F2R HLA-B HSPC043 ISGF3G (IRF9) LIAS PAK4 SELPLG TRB@
ADAM8 CD3Z FCER1G HLA-DMA HSPC129 ITGB2 LILRB4 PCDHGA8 SLC14A2 UBD
B2M CD53 FKBP14 HLA-DMB IFI30 KCNJ5 LOC90586 PSCD4 SMG1 UBE1L
BAX CD7 FLJ10244 HLA-DQB1 IGHG3 KCNK6 LOC92033 PSMB9 SORL1 UBE2B
BTN3A3 CD74 FLJ11106 HLA-DRA IGKC KIAA0924 LTB PSME1 STAT1 UBE2L6
C1QA CG012 FLJ11151 HLA-DRB1 IGLC2 KIAA1030 LTB4R RAB7L1 SULT1A3 UCP2
C4A CHD3 FLJ11467 HLA-DRB3 IGLC6 KIAA1170 MAFF RAC2 TAP1 WSX1 (IL27RA)
CASP4 CORO1A FY HLA-DRB5 IGLJ3 KIAA1257 MSH3 RARRES3 TAPBP ZAP70
CCL18 CTSS GMFG HLA-E IL2RB KIAA1348 NKG7 RASGRP2 TCBRV
(IL23A)
ZNRD1
CCL5 CX3CL1 GZMK HLA-F IRF3 LAT NM23-H6 RBL1 TNFAIP3 TNFSF13B
CXCL9 D21S2056E HA-1 HLA-G IRF5 LCK NPHP1 RIMS1
Reference: Saint-Mezard et al. 2008 (PARIS Dataset) [26]
Organ: Kidney
(PARIS+STANFORD+CLEVELAND+NON HUMAN PRIMATES Datasets)
ARHGDIB ARPC2 CASP1 CASP4 CCL5 CD163 CD44 CD48 CD52 CD53
CD8A CSPG2 CXCL10 CXCL9 FCER1G FER1L3 GBP1 GBP2 GMFG GZMA
HCK HCLS1 HLA-B HLA-C HLA-DMA HLA-DMB HLA-
DPA1
HLA-
DQB1
HLA-DQB2 HLA-DRA
HLA-
DRB3
HLA-E HLA-F HLA-G IFI30 IFITM1 IGHM IL10RA ISG20 ITGB2
LAPTM5 LCK LCP1 LCP2 LTF LYZ MMP7 NMI PLEK PLSCR1
PRG1 PRKCB1 PSMB10 PSMB8 PSMB9 RAC2 RUNX3 SERPING1 SLA STAT1
TAP1 TCIRG1 TIMP1 TNC TNFRSF7 UBD UBE2L6 WARS WFDC2 T3JAM
(TRAF3IP3)
Rodder et al. 2010 (TENON/INSELSPITAL Dataset) [29]
Organ: Kidney
Meta-analysis focused on metzincins and related genes
(TENON/INSELSPITAL+EDMONTON+STANFORD+ CLEVELAND Datasets)
TIMP1 MMP7 ADAMTS18 ADAMTS6 ADAMTS17 ADAMTS8 ADAMTSL4 ADAM18 TLL2 ADAM17
PLG LAMA4 EMILIN2
Chen et al. 2010 (STANFORD2 dataset) [27]
Organs: Kidney, Heart
(STANFORD2+CLEVELAND+SAN PAULO Datasets)
CXCL9 CXCL11 CXCR4 STAT1 CCL4 C6orf32 MARCKS IGSF6 CD2 TRPM1
IL10RA RARRES3 NR4A2 PTPRC LEF1 TAP1 CTSS ISG20 CCL8 BASP1
SLC2A3 LCP2 HLA-DMA BIRC5 HLA-DMB CASP4 SELL HLA-F CD44 HLA-DQB1
PIK3CD PECAM1 MDK MELK CDKN3 CPD SH2D2A CCNB2 HLA-DRA B2M
DIAPH1 USP34 SCAND2 RUNX1 S100A4
Genes underlining highly redundant themes among studies are in bold.
This table reports upregulated genes associated with acute allograft rejection detected by microarrays technology analyzing human graft samples
(bronchoalveolar lavage for lung samples, tissue biopsies for the other samples). Additional detail regarding the data extraction is provided in Additional file 1.
*Synonymous gene symbols, according to NCBI Gene, are provided in brackets.
#The original name reported in the publication was: TCR Active b-chain related gene (M12886: unmapped).
2# The original name reported in the publication was:
IL-2-stimulated phosphoprotein.
3#The original name reported in the publication was: ubiquitin.
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Page 4 of 22Table 2 Characteristics of microarray studies evaluating gene expression profile in acute allograft rejection biopsies in
humans.
Author
(dataset) *
Year
Organ
(samples)
Array
† Aim/Design
‡
Tannapfel et al.
[14]
2001
Liver (biopsies)
Atlas human cDNA
~ 600 genes
Aim. To investigate the expression of multiple inflammatory and apoptosis related genes in
acute allograft rejection.
Design. (Adults) 62 patients, 97 biopsies: acute allograft rejection (n = 32), HCV reinfection (n
= 18), CMV infection (n = 5), acute rejection and HCV infection (n = 3), stable graft function (n
= 30) and after treatment of acute rejection (n = 9).
Statistics. Not available.
Sreekumar et al.
[15]
2002
Liver (biopsies)
Affymetrix HU 6800
~ 6, 400 genes
Aim. To study intragraft gene expression patterns in acute cellular rejection and during
recurrence of HCV in HCV infected recipients.
Methods. (Adults) 8 patients and biopsies: HCV infection and acute cellular rejection (n = 4),
HCV infection without acute cellular rejection (n = 4).
Statistics. T-tests and fold change threshold.
Inkinen et al.
[16]
2005
Liver (biopsies)
Turku Centre of Biotechnology
human immunochip
~ 4, 600 genes
Aim. To determine and compare gene signature of CMV infection and acute rejection.
Methods. (Adults) 7 patients and biopsies: CMV infection (n = 4), patients with acute rejection
(n = 3).
Gene expression of CMV and acute rejection samples were compared to that of liver graft after
reperfusion.
Statistics. Not available.
Asaoka et al.
[28]
2009
Liver (biopsies)
AceGene Human chip
~ 30, 000 genes
Aim. To identify genes characteristic of acute cellular rejection in patients with recurrent HCV
infections.
Methods. (Adults) 21 HCV positive patients, 22 biopsies: acute cellular rejection (n = 9), without
acute cellular rejection (n = 13). The expression of some transcripts (CASP8 and BMP2) was
validated through qRT-PCR in this data set and also in a validation set: 32 biopsies from 25 HCV
positive patients.
Statistics. Class discovery: unsupervised clustering analysis. Class comparison: Mann Whitney U
test, supervised cluster analysis. Biological explanation: networks were built by Ingenuity
Pathway Analysis (IPA).
Gimino et al.
[17]
(Minneapolis
Dataset)
2003
Lung (BAL)
Affymetrix Human Genome
U133A
~ 18, 000 genes
Aim. To determine markers of acute rejection in lung recipients.
Methods. (Adults) 26 patients, 34 samples: acute rejection (n = 27), without diagnosis of
rejection (n = 7).
Statistics. Class comparison: significance analysis of microarray. Class description: supervised
clustering analysis.
Patil et al. [18]
(Minneapolis2
Dataset)
2008
Lung (BAL)
Affymetrix Human Genome
U133A
~ 18, 000 genes
Aim. to improve acute rejection diagnostics by identifying genes whose expression best
classifies acute rejection versus no rejection
Methods. (Adults) 32 patients, 32 samples: acute rejection (n = 14), without diagnosis of
rejection (n = 18). Expression of some transcript was also assessed through qRT-PCR.
Statistics. Class comparison: Significance analysis of microarrays.
Class prediction: prediction analysis of microarrays, method of nearest shrunken centroids with
10 fold cross validation. Biological explanation: Gene Ontology and GoHyperG.
Karason et al.
[19]
2006
Heart (biopsies)
Affymetrix Human Genome
U133A
~ 18, 000 genes
Aim. To utilize microarray analysis to search for potential biomarkers of cardiac allograft
rejection.
Design. (Adults). 20 patients, 14 patients experienced acute rejection episodes. 3 patients with
acute rejection and biopsy available at three different time-points (before: normal histology,
during: biopsy with acute rejection episode, after: biopsy with normal histology after the
rejection episode) were profiled. qRT-PCR was performed for selected genes (CXCL9, CXCL10,
NNPA). Serum levels of CXCL9 and -10 in 10 patients at three time points were also
determined.
Statistics. Gene clustering according to time-point analysis: self organizing map (SOM)
algorithm. Biological explanation: Gene Ontology (GO) and Netaffx.
Akalin et al. [21]
2001
Kidney
(biopsies)
Affymetrix
HU 6800
~ 6, 400 genes
Aim. To analyze gene expression profile using microarrays in acute allograft rejection.
Design. (Adults) 10 biopsies: histological evidence of acute cellular rejection (n = 7), without
evidence of rejection (n = 3).
Statistics. Each acute rejection sample was compared with each control sample. Genes with a
> fourfold increase in the majority of the samples were selected.
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Page 5 of 22Table 2 Characteristics of microarray studies evaluating gene expression profile in acute allograft rejection biopsies in
humans. (Continued)
Sarwal et al.
[22]
(Stanford
Dataset)
2003
Kidney
(biopsies)
Lymphochip
> 12, 000 genes
Aim. To investigate the possibility that variations in gene-expression patterns in allograft-biopsy
samples from patients with acute rejection and related disorders could identify molecularly
distinct subtypes of acute rejection to possibly explain differences in clinical behavior.
Design. (Pediatric patients) 50 patients. 67 biopsies: biopsies during acute or chronic allograft
dysfunctions (n = 52) and at the time of the engraftment or when graft function was stable (n
= 15). The possibility of different sampling of the medullary and the cortical regions was also
addressed.
Statistics. Class discovery: unsupervised clustering analysis. Class comparison: significance
analysis of microarray. Survival analysis: Kaplan-Meyer/Cox log-rank method. Biological
explanation: enrichment of specific functional groups through evaluation of hypergeometric
distribution. The exclusion of data from genes whose expression was correlated with the depth
of biopsy did not change the cluster analysis.
Flechner et al.
[23]
(Cleveland
Dataset)
2004
Kidney
(biopsies and
PBLs)
Affymetrix
HG-U95Av2
~ 10, 000 genes
Aim. To determine gene expression profiling in transplant patients including: normal donor
kidneys, well functioning transplants without rejection, kidneys undergoing acute rejection, and
transplants with renal dysfunction without rejection.
Design. (Adults) 23 graft recipients and 9 donors. Acute rejection biopsies (n = 7), renal
dysfunction without rejection on biopsies (n = 6), biopsies carried out more than one year post
transplant in patient with good transplant function and normal histology (n = 10), biopsies
from living donor controls (n = 9). PBLs were also collected and profiled. Expression of some
transcript was also assessed through qRT-PCR.
Statistics. Class discovery: unsupervised clustering analysis. Class comparison: significance
analysis of microarray filtered with limit fold model and MAS 5.0 present/absent calls. Class-
prediction: leave-one-out method. Biological explanation: analysis of functional classes of the
differentially expressed genes.
Reeve et al. [24]
(Edmonton
Dataset)
2009
Kidney
(biopsies)
Affymetrix Human Genome U133
Plus 2.0
> 38, 000 genes
Aim. To define a classifier to distinguish rejection vs non rejection using predictive analysis for
microarrays.
Design. (Adults) 143 patients, 186 biopsies: acute rejection samples (acute cellular rejection,
antibody mediated rejection or mixed) (n = 51), non-rejection samples (n = 135).
Statistics. Class comparisons: Bayesian t-test and false discovery rate. Class prediction:
prediction analysis of microarrays. Biological explanation: analysis of functional classes of the
differentially expressed genes according to KEGG pathways and to authors’ defined
pathogenesis-based transcripts.
Morgun et al.
[25]
(San Paulo
Dataset)
2006
Heart (biopsies)
Qiagen/Operon Array
~ 14, 000 genes
Aim. To analyze gene expression differences between rejection, non rejection and
Trypanosoma cruzi infection.
Design. (Adults) 40 patients, 76 biopsies (rejection, no rejection and Trypanosoma cruzi
infection recurrence). Expression of some transcripts was also assessed through qRT-PCR.
Statistics. Class comparison: random variance t-test filtered with univariate/multivariate tests for
false discovery rates; supervised clustering analysis. Class prediction: 6 different multivariate
models models (compound covariate predictor, diagonal linear discriminant analysis, 1- and 3-
nearest neighbor predictor, nearest centroid predictor, support vector machine) and leave-one-
out cross validation. The authors validated the predictor-set in independent datasets of biopsies
(collected on different continents and analyzed with different chip batches). The authors also
tested the predictor set by analyzing the data from data from Cleveland (Kidney) Stanford
(Kidney) and Minneapolis (Lung) datasets.
Biological explanation: Database Annotation, Visualization and Integrated Discovery (DAVID)/
Gene Ontology and KEGG Pathways.
Saint-Mezard et
al. [26]
(Paris Dataset)
2008
Kidney
(biopsies)
Affymetrix Human Genome U133
Plus 2.0
> 38, 000 genes
Aim. To identify a robust and reliable molecular signature for acute rejection in humans.
Design. (Adults) 45 patients, 47 biopsies: acute rejection (n = 8), acute rejection and chronic
allograft nephropathy (n = 8), borderline (n = 3), non rejection (n = 7), and chronic allograft
nephropathy (n = 22). Normal kidney tissue was obtained from histopathologically unaffected
areas of the cortex of native nephrectomies performed for renal carcinoma was used as
control.
Statistics. Genes differentially expressed (Paris Dataset) were intersected with those from with 2
public human datasets: 1) Stanford Dataset and 2) Cleveland Dataset and with one Non Human
Primate (NHP) model of acute renal allograft. However, the authors used biopsy microarray data
from Edmonton Dataset as in independent confirmation set. Score from the identified classifier
was correlated with the histopathological Banff score. Expression of some transcripts was also
assessed through qRT-PCR.
Class comparison: ANOVA with or without false discovery rate and additional cutoff based on
twofold change. Class discovery: Principal component analysis, supervised clustering analysis
(using the genes differentially expressed in all four datasets); Class prediction: leave-one-out
cross-validation and 10-fold cross-validation. Biological explanation: Gene regulatory networks
were generated using MetaCore.
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Page 6 of 22by different investigators in different organs (see Table
1). Figure 1 provides a visualization of the relationships
among the key genes described. Here, we attempt to
illustrate the hypothetical role of these pathways during
acute allograft rejection.
IFN-g pathway
IFN-g is a pleiotropic cytokine that plays a role in the
modulation of many aspects of the immune response.
Studies conducted involving IFN-g -/- mice suggest that
this cytokine, in addition to its pro-inflammatory func-
tions, might be important for graft acceptance, prevent-
ing early graft necrosis, and maintaining microvascular
viability [52,53]. However, the molecular mechanisms
through which IFN-g exerts its anti-inflammatory action
during the early phases of the engraftment are unclear.
On the other hand, this interferon is considered a cen-
tral cytokine in sustaining inflammation during allograft
rejection both in humans and in murine models.
IFN-g is predominantly produced by NK cells as part
of the innate immune response, and by CD4 T helper 1
cells (Th1) and CD8 cytotoxic T cells (CTLs) as a part
of the adaptive immune response once antigen-specific
immunity develops [54,55]. Its overexpression has also
been observed in acute allograft rejection in several
human studies where RT-PCR was applied [17,56-58].
Microarray studies have not only enabled the detection
of the expression of the IFN-g gene itself, but also the
detection of its downstream effects (IFN-g stimulated
genes) [15,17,21-24,59]. Figure 1A represents the first
network generated by IPA after analysis of the compiled
list of key immune-related genes (Table 1), with IFN-g
serving as the hub of this important network. Detection
of IFN-g stimulated genes alone is not sufficient to dis-
criminate its effect from the effects of other cytokines,
such as IFN-a, which can also activate many of the
IFN-g stimulated genes [60,61]. However, the prevalence
of IFN-g versus IFN-a transcripts in addition to the acti-
vation of pathways that specifically enhance the INF-g
loop (e.g. TNF-a,C C R 5 ,a n dC X C R 3 )i m p l i c a t eI F N - g
as a driver gene involved in sustaining acute allograft
rejection [22,24,26,31,59,62]. Although some functions
have been described for individual IFN-g stimulated
genes, the overall orchestration is not completely under-
stood. A partial description of the relationship among
IFN-g stimulated genes detected in microarray studies is
illustrated in Figure 1A.
Primarily through interferon regulatory factor 1 (IRF-
1), IFN-g u p r e g u l a t e sb o t hM H Cc l a s sIa n dI I ,b y
increasing the expression of antigen peptide transporters
TAP1-2, or class II transactivator CIITA, for example
[54,63,64]. Indeed, IFN-g promotes the differentiation of
naïve CD4 T cells into Th1 cells which are, among the
lineage of CD4 T cells (Th1, Th2, Th17 and T Reg), the
only ones that produce a consistent amount of IFN-g
Table 2 Characteristics of microarray studies evaluating gene expression profile in acute allograft rejection biopsies in
humans. (Continued)
Rodder et al.
[29]
(Tenon/
Inelspital
Dataset)
2011
Kidney
(biopsies)
Affymetrix Human Genome U133
Plus 2.0
> 38, 000 genes
Aim. To identify the expression of metzincins and related genes in allograft rejection biopsies.
Design. (Adults) 41 biopsies: normal histology (n = 20), borderline changes (n = 4), acute
rejection (n = 10) and acute rejection and interstitial fibrosis/tubular atrophy (n = 7). Expression
of some transcripts was also assessed through qRT-PCR.
Statistics. Class prediction: ANOVA and shrinking centroids methods were used for variable
selection and a variety of classification methods were tested. Leave-one-out method was
performed as internal cross-validation. Classifier performance was estimated as correct rate after
1-level cross validation. The model was validated in Edmonton, Cleveland and Stanford
datasets. Gene set scores from biopsies were also determined and correlated with Banff scores.
Chen et al. [27]
(Stanford2
Dataset)
2011
Kidney
(biopsies)
Affymetrix Human Genome U133
Plus 2.0
> 38, 000 genes
Aim. To identify biomarkers across similar conditions through integration of related datasets.
Methods. (Pediatric patients) 36 patients and biopsies: acute rejection biopsies (n = 18), stable
function biopsies (n = 18).
Statistics. Class comparison: significance analysis of microarrays and fold change filter. The
upregulated genes during acute rejection were intersected with genes upregulated during
acute rejection in two other datasets (Cleveland and San Paulo).
Notes
*For the Minneapolis Dataset only the publication by Gimino et al. is described;
†Microarray chips details: Atlas human cDNA microarrays ~ 588 gene analyzed; Affymetrix GeneChip HU6800 Array containing > 7, 000 oligonucleotide probe
sets representing ~ 6, 400 human genes (Affymetrix, Santa Clara, CA);
Affymetrix Human Genome U133A Array containing > 22, 000 oligonucleotide probe sets representing > 18, 000 transcripts (~ 14, 500 human genes) (Affymetrix,
Santa Clara, CA); Lymphochip: in-house microarrays containing > 28, 000 cDNA probes representing > 12, 000 genes (Stanford University); Affymetrix GeneChip
HG-U95Av2 Array containing ~ 12, 000 oligonucleotide probes representing ~ 10, 000 human genes; Affymetrix Human Genome U133A Array containing > 22,
000 oligonucleotide probe sets representing > 18, 000 transcripts (~ 14, 500 human genes) (Affymetrix, Santa Clara, CA); Affymetrix Human Genome U133 Plus
2.0 Array containing > 54, 000 oligonucleotide probe sets representing > 47, 000 transcripts (~ 38, 500 human genes) (Affymetrix, Santa Clara, CA); Qiagen/
Operon array: in-house oligonucleotide array platform designed by Qiagen/Operon (Alameda, CA) and printed at NIAID Microarray facility, representing ~ 14, 000
human genes;
‡Study aim/design is referred to gene expression experiments;
Abbreviations: BOS: Bronchiolitis obliterans syndrome; PBLs: Peripheral blood lymphocyte; CMV: cytomegalovirus; HCV: hepatitis C virus; qRT-PCR: quantitative real
time polymerase chain reaction;
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tumor necrosis factor-a (TNF-a), induces the expres-
sion of CXCR3 ligands [54,66,67] and CCR5 ligands
[68].
CXCR3 and CCR5 ligand pathways
CXCR3 ligands (CXCL9, -10, -11) and CCR5 ligands
(CCL3, -4, -5) are the chemokines most frequently upre-
gulated during acute allograft rejection as described by
human microarray studies [18,21-27] and RT-PCR (See
Table 1). The upregulation of the related receptors,
CXCR3 and CCR5, has also been frequently described,
though not as much specifically within microarray stu-
dies [17,22,24,69-72]. Interestingly, high urinary CXCR3
ligand protein levels were detected in clinical trials in
patients experiencing acute kidney rejection [48-51].
More recently, Chen et al. [27] described CXCL9 as a
biomarker of acute rejection in a cross-organ microarray
study evaluating pediatric renal, adult renal, and adult
cardiac transplant patients. Additionally, CXCL9 pro-
teins were also found to be elevated in serum. Indeed,
the CCR5Δ32 polymorphism that encodes for a non-
functional CCR5 receptor, conferred a greatly reduced
risk for the development of acute rejection in kidney
[73] and in liver transplantation [74].
The driving role of these two pathways in allograft
rejection was suggested by in vivo murine models one
decade ago [75-78]. The lack of host CCR5 was asso-
ciated with a three-fold increase in allograft survival
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Figure 1 First 5 Immune networks according to Ingenuity Pathways Analysis (IPA), representing schematic relationships among key
genes upregulated in acute allograft rejection (Network number 1 (A), 2 (B), 3 (C), 4 (D) and 7(E), generated by IPA). The gene list
uploaded represents the key gene list (Table 1). Red: The genes and gene complexes from the key gene list are represented in red background
(no color fill is used for the genes that are part of the network but not part of the key gene list). Blue: IFN-g stimulated genes (designated IFN-g
stimulated genes identified as those upregulated in peripheral monocytes after IFN-g stimulation). A. the first network is centered around IFN-g;
B. the second network is centered around TNF- a; C. the third network focuses on Interferon Regulatory Factors (IRFs) and chemokine/
chemokine receptor interaction (i.e., CCR5/CCR5 ligands and CXCR3/CXCR3 ligands); D. the fourth network focuses on Immune Effector Function
(IEF) genes (i.e., around granzyme B, perforin, caspases); E. the fifth network is centered around the NF-kB complex. Bold lines indicate direct
interaction. Dotted lines indicate indirect interaction.
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using knockout mice or monoclonal antibodies had no
effect on allograft survival [79]. Similarly, lack of CXCR3
led to graft acceptance indefinitely [75] and in addition,
a significant survival benefit has been observed in
CXCL10 -/- recipients [76]. This supposed non-redun-
dant effect of CXCR3 that has been assumed correct for
almost ten years, is currently object of debate [80].
Recently, in fact, two independent studies reported that
disruption or blockade of recipient CXCR3 had rela-
tively little effect on rejection [81-83]. These observa-
tions, as well as the abundance of CXCR3 ligands
present during acute allograft rejection, raise questions
about the functional importance of CXCR3 during rejec-
tion and the possibility of alternative targets of CXCR3
ligands [80].
Upon antigen stimulation, the co-expression of
CXCR3 and CCR5 is a marker of Th1 cell polarization,
whereas CCR3, CCR4, CCR8, and CRTh2 are expressed
by Th2 cells [65]. The genes and gene pathways fre-
quently overexpressed during acute allograft rejection
are consistent with the predominance of Th1 cell polari-
zation. Among CXCR3 and CCR5 ligands, CXCL9, -10
and CCL4, -5 were the most frequently reported chemo-
kines associated with acute rejection in microarray stu-
dies [19,21-24,31] (see Table 1).
CCR5 and CXCR3 ligands can be secreted differen-
tially by dendritic cells, activated macrophages and T
cells, endothelial cells, and NK cells [69,70,84-87]. How-
ever, studies that define the cell-specific production of
chemokines in allograft rejection in humans are scant.
Consequently, evidence-based descriptions of cell-speci-
fic chemokine-mediated recruitment have not been
well-defined in humans either.
Hoffmann et al. [88] described that a significant pro-
portion of both CD4+ and CD8+ T-cells detected in
human renal biopsies during rejection express CXCR3.
It has also been speculated that CXCR3 may act as a
decoy receptor by binding CCL11, preventing the
recruitment of granulocytes via the CCL11/CCR3 bind-
ing interaction [80,89]. This might explain why granulo-
cytes are not classically found in acute cellular rejection.
Furthermore, peripheral blood monocytes that are lower
in CCR5 expression could be recruited through CCR1
t h a ta l s ob i n d sC C L - 3 ,- 4 ,- 5 .I na d d i t i o nt oT h 1a n d
CTL cells, NK cells could also possibly be recruited
through this pathway since they are all known to
express CXCR3 and CCR5 receptors [85]. However, NK
cells are rarely present in allograft infiltrates and are
especially rare in T-cell mediated rejection [39,90].
Recruitment and activation of CCR5 and CXCR3
ligands can lead to increased production of IFN-g,w i t h
a resultant amplification of the inflammatory stimuli
and further release of chemoattractant molecules. Thus,
in a concerted fashion, these molecules orchestrate the
switch from innate to adaptive immunity, meanwhile
sustaining and strengthening the innate cytotoxic
mechanisms with a persistent “NK-like” response.
Finally, even though up to 25% of circulating B cells
express CXCR3 [90-92], and can also produce CXCR3
ligands [87,93], the recruitment of B cells through this
mechanism during acute allograft rejection has not yet
been defined in humans.
This complex cascade of cytokines and the coordinate
activation of specific pathways so far described, leads to
the activation of IEF genes (perforin, granzymes A/B,
Fas/Fas ligand, and caspases) during the process of tis-
sue destruction.
IEF genes
The release of granzymes, perforins, and granulysin and
the interaction between the Fas/Fas ligand and caspase
activation represent the major effector mechanisms of
cell-mediated immunity [94]. These IEF transcripts have
been consistently described as being associated with
acute allograft rejection using transcriptome analyses
[17,22,23,26].
By profiling PBMCs, Hidalgo et al. [40] found that
cytotoxic molecular transcripts (i.e. granzyme B, Fas
ligand, perforin) are commonly overexpressed in CTL
CD4+ cells, CTL CD8+ cells, and NK cells. These obser-
vations highlight the existence of a common molecular
cytotoxic “NK-like” effector mechanism that is shared
among the different arms of the immune system, the
classically distinct innate a n da d a p t i v ei m m u n ea r m s .
Taking this one step further, Mueller et al. [31] found
that gene expression patterns of T-cell mediated rejec-
tion are surprisingly similar to the expression patterns
found in antibody-mediated rejection. In particular,
interferon-g affected transcripts and IEF genes such as
perforin, granzyme B, and Fas ligand were overexpressed
in both of them. This observation suggests that effector
T cells and antibodies lead to the activation of a com-
mon final pathway in tissue destruction and supports
t h ep r o p o s e dt h e o r yo ft h ei m m u n o l o g i cc o n s t a n to f
rejection [3].
NK cell, B cell, and T-reg signatures
NK signature
NK cells in murine skin and rat liver allografts are the
immune cells responsible for early chemokine produc-
tion of CCR5 and CXCR3 ligands (i.e., CCL3, CCL4,
CXCL10) which are important in initiating and sustain-
ing acute allograft rejection [95,96]. Nevertheless, NK
cells do not seem to be sufficient to reject solid organs
directly since mice that have intact NK cell function but
absent adaptive immunity (RAG
-/- or SCID) are able to
accept skin and cardiac graft transplants indefinitely
[97-99]. However, the inability to reject the graft does
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unable to mediate tissue destruction. A possible expla-
nation could be that, in these models, the lack of stimuli
derived from a reciprocal feedback between innate and
adaptive cells, does not allow triggering or sustaining a
strong enough “NK-like” cytotoxic effector function.
Recently it has been observed that nude mice treated
with oncolytic viruses can reject tumor xenografts [100].
This rejection was associated with the activation of ISGs
(both IFN-g and IFN-a stimulated genes), upregulation
of CXCR3 and CCR5 ligands, and activation of IEF
genes (granzyme B, caspase 8). Since these mice lack T
cells and secondarily lack B cell responses, this immune-
mediated tissue destruction is thought to be induced by
innate immune effectors such as NK cells and activated
macrophages. This study suggests that, at least in this
model, innate immunity can be an independent effector
of tissue-specific destruction not requiring adaptive
immunity. It is possible that the oncolytic virus used in
this model primes the innate immune system in a man-
ner that bypasses the need for the adaptive immune sys-
tem interaction.
In humans, however, studies analyzing the individual
contribution of innate immune cells in mediating the
final step of the alloresponse are lacking. Although NK
cells are present, they are only a minor component of
allograft tissue infiltrates in acute rejection [98,101,102].
For this reason they are traditionally thought to exert
only a marginal role. Therefore, the study conducted by
Hidalgo et al. [39] was remarkably revealing. The inves-
tigators compared the gene expression profiles of anti-
body-mediated rejection in humans by analyzing the
gene expression profiles in biopsies from patients with
donor specific antibody. In these antibody-mediated
rejection samples there was a strong expression of IFN-g
associated transcripts and NK cells. Immunohistochem-
ical staining displayed more NK cells and macrophages
in antibody-mediated rejection than in T-cell-mediated
rejection. These findings suggest that the frequent
observation of IEF gene upregulation not only during T
cell mediated rejection but also during antibody
mediated rejection could reflect the activation of com-
mon “NK-like” effector functions. Recently, tolerant
patients have been found to have an expansion of NK
cells and overexpression of NK transcripts in peripheral
blood. These findings helped generate new hypotheses
on the role of NK cells in balancing tolerance and med-
iating rejection [103].
B cell signature
The precise role that B cells play in acute allograft rejec-
tion is still being discovered. Recent high-throughput
studies have exposed the multi-faceted role of B cells
within allografts. With some evidence to suggest a sig-
nificant role for B cells in mediating rejection, other
evidence also suggests a role for B cells in tolerance.
The B cell is an enigma and the details of its functions
must be further elucidated.
In a breakthrough paper in 2003, Sarwal et al. [22] found
an enrichment of B cell transcripts in pediatric renal biop-
sies experiencing acute rejection. This unexpected B-cell
signature was also confirmed by immunohistochemistry.
Although ectopic germinal center formation with B-cell
activation and plasma cell activation can occur locally in
chronically inflamed tissue [104,105], the in situ presence
of B cells was not historically reported in acute allograft
rejection [22,106,107]. This CD20+ B cell infiltration was
not associated with intra-graft C4d deposition (required by
Banff criteria for diagnosis of acute antibody-mediated
rejection) [108] or with the detection of donor-specific
antibodies, indicating that it was not necessarily related to
the presence of humoral response. The presence of such
CD20+ dense clusters in a significant proportion of sam-
ples from patients diagnosed with acute allograft rejection
would, thereafter, be confirmed by several independent
studies [109-116], with incidence varying from 15% to 60%
[38,113,116]. However, the correlation with poor outcome
suggested by Sarwal et al. [22] was confirmed by some stu-
dies [112,114,115,117] but not by others [38,109-111,113]
and seemed more likely associated with late inflammation
in allograft rejection [38]. B cell transcripts have also been
detected to be upregulated during acute rejection in lung
and heart transplants (Table 1) [17,25].
The subsequent lineage analysis revealed that CD27+
and chronically activated CD79+, CD20+ B cells expressed
HLA antigens and were surrounded by CD4+ T cells. This
suggests a putative role for these cells in antigen presenta-
tion, driving a T-cell dependent cellular rejection [118].
Another cluster of B cells was represented by CD138+
mature plasma cells [118]. Recently, studies conducted in
heart transplantation models showed that a deficiency in B
cell mediated antigen presentation leads to lack of CD4 T
cell activation and alloantibody production [119]. Other in
vivo observations pointed to the possible pivotal role of B
cells in the context of pathogen- [120,121] or autoim-
mune- [122] induced T cell response. Interestingly, B cell
infiltrates have been associated with favorable outcome in
early breast cancer patients [123]. However, in addition to
functioning as antigen presenting cells, B cells may pro-
mote T cell mediated rejection by producing chemoattrac-
tant molecules such as CXCR3 ligands (CXCL9, -10, -11)
[87].
Despite the elegant rationale behind the use of an
anti-CD20 monoclonal antibody (rituximab) in trans-
plantation, this treatment showed only partial efficacy
when tested in randomized trials [124-126]. Although
rituximab depletes CD20+ CD27- naïve and CD20+
CD27+[127] memory cells, it is not active on plasma
cells that are CD20- and are thought to be implicated in
Spivey et al. Journal of Translational Medicine 2011, 9:174
http://www.translational-medicine.com/content/9/1/174
Page 10 of 22the pathophysiology of acute antibody-mediated rejec-
tion. Additionally, two high-throughput studies evaluat-
ing several parameters in peripheral blood [103,128] and
urine [128] of patients with drug-free spontaneous renal
allograft tolerance found an expansion of B-cells in per-
ipheral blood, confirming a previous report [129]. The
particular phenotype of these B cells seems to be repre-
sented by an expression of memory activated B-cells
and increased expression of inhibitory molecules [130].
These observations could explain the increased rate of
rejection reported in rituximab-treated patients in a
recent randomized controlled trial that was forced to
stop prematurely [126]. With B-cells implicated in both
rejection and in tolerance, their precise functions remain
puzzling.
T-reg signature
The recent detection of the association between the tran-
scription factor forkhead box 3 (FOXP3) transcripts and
acute rejection deserves comment. The recruitment of
CD25+, FOXP3+ T regulatory cells (T-regs) is a well-
defined mechanism for controlling autoimmunity in
humans and animal models. It is known that humans car-
rying X-linked FOXP3 mutations manifest an autoimmune
syndrome consisting of immune dysregulation, polyendo-
crinopathy and enteropathy, termed IPEX syndrome.
Additionally, FOXP3 knockout mice manifest severe auto-
immune diseases as well [131,132]. However, the presence
of FOXP3+ cells and/or the expression of FOXP3 are not
always associated with a decreased immune response and
their biological significance remains unclear. Interestingly,
the pre-treatment presence of FOXP3+ T cells was asso-
ciated with favorable outcome in colon cancer patients
undergoing chemotherapy or immunochemotherapy
[133,134]. In kidney transplantation, however, higher
FOXP3 transcripts in cells obtained from urine samples
was associated with acute rejection [135]. Additionally, in
another study, FOXP3 expression was found to be higher
in antibody-mediated and T-cell mediated acute rejection
samples than it was in the non-rejection samples [136].
Since FOXP3 mRNA directly correlated with post-trans-
plantation time the authors speculated that FOXP3 posi-
tive cells possessed the key to control the potential for
autoimmunity in these sites rather than representing a
cognate immune-response. Nevertheless, it is presently
unclear if FOXP3 (acting as a transcription factor) can
modulate the immune-response per se through unknown
independent pathways.
TNF-a, Complement and IL-10: the link between the
innate and adaptive immunity
TNF-a
The upregulation of the TNF-a pathway is another sig-
nature often associated with acute allograft rejection
(Table 1, Figure 1B). Many of the genes expressed
during allograft rejection are associated with innate
immunity: TNF-a,u b i q u i t i n ,C 3 ,H e a ts h o c kp r o t e i n7 0
(HSPA1A, which is the endogenous ligand of Toll-like
receptor (TLR)-4) [137,138] and IRF-9 (a protein that
interacts with STAT-1 and STAT-2 to form ISGF3, a
transcription factor for IFN-a) [139,140].
The presence of TNF-a is not indicative of acute
inflammation, and it is typically also present in chronic
inflammation [3,141,142]. Although the transformation
from an indolent process to an acute one is unknown, it
seems plausible that an innate stimulus that leads to
increased TNF-a, could help elicit a cascade of events
associated with acute response [3]. Rather than the
increase of TNF-a per se, these stimuli could produce a
series of interconnected events, of which TNF-a upre-
gulation might be one of the consequences. For exam-
ple, the engagement of toll-like-receptors (TLRs) by the
endogenous danger-associated molecules (the rise of
which can be caused by the intervention itself or by the
ischemic-reperfusion injury) [97,143], may lead to NF-
kB (nuclear factor kappa B) activation and transcription
of NF-kB induced genes, including TNF-a [144]. TNF-a
is a potent activator of NF-kB, thereby amplifying a
positive feedback mechanism. Moreover, NF-kB, by
inducing transcription of CXCR3 and CCR5 ligands
[144], could trigger and sustain the IFN-g cascade by
promoting the migration of IFN-g-producing Th1 cells,
cytotoxic T cells, and NK cells. Concurrently, the activa-
tion of TLRs on antigen presenting cells (APCs) could
also enhance antigen presentation and induce upregula-
tion of co-stimulatory molecules, promoting adaptive
responses and recruiting CTLs [145,146], with further
amplification of the immune response.
In allograft rejection, the continuous and abundant
availability of antigens from the surface of donor cells,
and the interaction with T and possibly with B cells
(directly through interaction of B cell receptor and
MHCs) cause a labile condition particularly vulnerable
to being switched to a destructive acute response. Thus,
whether this condition is sufficient per se to determine
an acute response (according to the self non-self model)
or needs to be prompted (in accordance with the danger
model), is object of ongoing debate [137,147].
In conclusion, we could hypothesize that both innate
and adaptive mechanisms synergize in generating/sus-
taining the immune response. Indeed, the dual presence
of such strong stimuli leads almost inevitably to a pro-
gressive destructive response, thereby requiring lifelong
immunosuppression, with the exception of the rare
cases of spontaneous tolerance [103,128,148].
Complement
Complement is the archetypal innate defense mechan-
ism and provides a vital link between innate and adap-
tive functions [149-151]. Briefly, the central event in
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vated by antibodies or microbial cell surfaces) to gen-
erate biologically active products that lead to the
formation of membrane attack complexes that result in
the activation of granulocytes and cell lysis [149-151].
The majority of complement is synthesized in the liver;
however, local sources of complement include
endothelial cells, macrophages, neutrophils, and epithe-
lial cells (particularly renal tubular epithelial cells). The
molecular pathways that lead to the activation of com-
plement transcription during the alloresponse are not
completely clear, but activation of the NF-kB pathway
has been suggested to be a potential stimulus for local
C3 production [152,153]. It has been proposed that C3
could also be responsible for the Th1 response
observed during allorejection, directly by sustaining
Th1 development [154], or indirectly by inhibiting Th2
polarization [155]. Priming C3 deficient mice with den-
dritic cells led to delayed skin allograft rejection. Addi-
tionally, complement can activate B cells and initiate
humoral responses [156]. In kidney transplantation in
animal models, it has been shown that local renal C3
production leads to faster allograft rejection [157,158].
However, opposing results were reached in three inde-
pendent studies analyzing liver transplantation in ani-
mal models. In these cases, an association between
overexpression of C3 and tolerance was found
[159-161]. Thus, at least in animal models, it is possi-
b l et oh y p o t h e s i z et h ee x i s t e n c eo fd i v e r s er e g u l a t o r y
mechanisms in different organs.
The presence of C4d (a C4 split product) by immuno-
histochemical staining is a feature associated with anti-
body-mediated rejection since it can activate the
classical pathway of complement. Since the majority of
circulating complement is produced by the liver, com-
plement is not typically detected by microarray analysis.
Thus, detection of complement transcripts during acute
allograft rejection by gene expression suggests local pro-
duction within the graft.
C3 and/or other complement components (C1 and
C4) have been associated with acute allograft rejection
in several microarray studies conducted in renal [23,21],
liver [15], heart [19,25], and lung [17] transplants. Cur-
rently, interest in the role of complement in the regula-
tion of the alloresponse is rising [149,150,162]. In a
recent study conducted by Naesens et al. (Stanford
group [162]), the authors observed upregulation of com-
plement genes before transplantation in deceased donor
kidney biopsies compared to living donors. In the same
publication, the authors reported a significant overex-
pression of genes involved in the complement cascade
(including C1 and C3) when comparing 32 acute rejec-
tion samples to 20 non-rejection samples obtained from
pediatric kidney recipients [162].
IL-10
Contrary to the popular belief that IL-10 is principally
an anti-inflammatory cytokine, the IL-10 pathway is fre-
quently described as upregulated during acute allograft
rejection in kidney and liver transplants in humans
[14,23,26] (Table 1).
Although the canonical effects of IL-10 are regulatory
and function in the termination of inflammatory pro-
cesses [163], this cytokine cannot merely be classified as
anti-inflammatory, due to its pleiotropic ability to both
positively and negatively influence the function of innate
and adaptive immunity in pre-clinical models [164-166].
In humans, intravenous administration of recombinant
IL-10 produces pro-inflammatory effects by enhancing
the release of IFN-g,T N F - a, and IL-1, and appears to
induce the activation of CTLs and NK cells, as reflected
by increased plasma levels of granzyme-B [167,168].
Interestingly, high levels of serum IL-10 were associated
with anti-tumor response in a clinical trial involving
metastatic melanoma patients treated with immuno-
chemotherapy (i.e., bevacizumab and fotemustine) [169].
In human monocyte lineage cells, IL-10 increases the
expression of TLRs, which might sensitize these cells to
‘danger signal’ mediators. This suggests that IL-10 plays
a key role in the early phases of the acute immune
response. Systemic administration of IL-10 exacerbates
alloreactions in murine models [170,171], and, accord-
ingly, the administration of anti-IL-10 monoclonal anti-
body prolongs graft survival [172]. In addition, by
inhibiting APC maturation and postponing their migra-
tion to lymph nodes, this cytokine may lead to more
efficient antigen loading, and might activate locally
adaptive effectors [164-166]. In humans, post-transplant
levels of IL-10 [173] and a specific IL-10 polymorphism
[174] were associated with risk of acute rejection in kid-
ney transplants.
The evidence provided supports IL-10 involvement in
tumor rejection and allograft rejection in humans, and
suggests that this cytokine defies its reputation of having
solely anti-inflammatory properties.
IRF-1 and STAT-1
By using MetaCore algorithms, IRF-1 and STAT-1 were
predicted to be regulators of several of the key tran-
scripts after analysis of our key genes list extracted from
microarray studies (Figure 2). IRF-1 is an inducible IFN-
g transcription factor and it is transcribed in response to
IFN-g via STAT-1 [54,175]. This transcription factor
could mediate the upregulation of several gene/gene
pathways during acute allograft rejection, as shown in
Figure 2. Genes upregulated by IRF-1 include pro-
inflammatory cytokines (e.g. TNF-a [176]), chemokines
(e.g. CXCL10 [66,67], CCL5 [68]), and MHC class I and
class II molecules [54,177]. It could also drive the synth-
esis of IL-10 RA [66]. Another important pro-
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IL-12 [178] and IL-15 [179] with consequent enhance-
ment of the IFN-g cascade.
IRF-1 has been better described with relation to tumor
rejection. In a study conducted in melanoma patients by
Wang et al. [2], IRF-1 was the most significantly and
consistently upregulated transcript in metastatic mela-
noma lesions undergoing clinical regression after the
systemic administration of high-dose interleukin-2. IRF-
1 appeared to play a central role in orchestrating the
immune response, generating the switch from chronic
to acute inflammation in this as well as several subse-
quent studies [3,4].
Regarding the allograft, although statistical algorithms
recognize IRF-1 as one of the main transcription factors
that regulate genes involved in acute allograft rejection,
it should be noted that its overexpression per se has not
yet been identified as relevant according to human
microarray studies. Thus, these data must be interpreted
cautiously. Nevertheless, STAT-1 has been massively
described as upregulated during acute allograft rejection
(see Table 1), suggesting the regulation of IRF-1 through
the IFN-g/STAT-1 pathway as a plausible mechanism.
In a recent mouse liver transplant model microarray
study, IRF-1 was one of the two genes overexpressed
both in leukocytes and intragraft during acute cellular
rejection (GBP2 was the other gene, also an IFN-g indu-
cible gene) [180]. Accordingly, studies have reported an
association between IRF-1 and acute cellular rejection in
heart transplant models [181,182]. On the other hand,
other groups have reported STAT-1/IRF-1 pathway to
be upregulated in tolerant models [159,160]. In order to
ImmuneEffectorFunctionGenes CCR5/CCR5Ligands
IFNͲɶ CXCR3/CXCR3Ligands
Figure 2 Transcription Regulatory Network Analysis according to MetaCore algorithms. This figure shows possible genes regulated by
STAT-1 and IRF-1. The gene list uploaded represents the key gene list (Table 1).
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tion of T cell apoptosis by IFN-g signaling [159]: the
transcripts STAT-1 and IRF-1 were also found to be
involved in the induction of apoptosis via a caspase-
mediated mechanism [183] (Figure 2). Thus, it is likely
that IRF-1 plays a different role according to the inde-
pendent co-activation of different pathways, which can
greatly differ from cell to cell but can also vary with
changes in the surrounding environment [183].
Although IRF-1 seems to be regulated primarily by
IFN-g signaling [175], in vivo and in vitro observations
suggested that IRF-1 regulation does not necessarily
require the interaction of this cytokine. Indeed, IRF-1
has been observed in response to IL-2 stimulation in
vitro [184] and in the absence of interferon upregulation
in animal models [100]. In addition, IRF-1
-/-mice have
defects not observed in IFN-g or IFN-g- receptor
-/- ani-
mals, (such as alterations in CD8+ T cells and thymo-
cyte development), supporting the existence of an IFN-
g-independent activation pathway of IRF-1, [54,185].
Vice versa, even supposing a central role for this protein
in the induction of pro-inflammatory mediators, a
recent microarray study in heart transplanted mice sug-
gested that IRF-1 functions could be bypassed by other
mediators [186]. That same study showed that the
expression profile of the allograft from IRF-1
-/- mice
and wild type mice were nearly identical to each other
and very different from the profile of isograft control.
Comparative analyses
Despite discrepancies among different studies, cross-
comparison of datasets has been remarkably revealing
[25,26], probably because of the highly conserved mole-
cular patterns associated with immune-mediated tissue
destruction. The first comparative analysis was per-
formed by Morgun et al. [25] who, after identifying a
gene set predictive of acute-rejection in a series of heart
allograft recipients, analyzed the data from two pub-
lished studies on kidney (Stanford dataset [187] and Cle-
veland dataset [23]) and lung (Minneapolis dataset [17])
transplants. The authors observed a striking agreement
with the histological diagnosis of the three studies. The
predictive accuracy of the gene set obtained from study-
ing hearts was close to 95% in kidney and lung acute
rejection illustrating the similarity of activated pathways
from different rejected organs. Similar to observations in
renal transplants [22], B cell transcripts (immunoglobu-
lins) were among the most upregulated, suggesting that
B cells may also have a local effect in heart rejection.
Another interesting finding was the similar pattern of
immune-response-related gene expression (antigen pre-
sentation, innate immunity, chemotaxis, immunoglobu-
lins and cytokines) among samples with diagnosis of
acute rejection versus infection. Here, the gene
expression pattern of transplant recipients who under-
went rejection was similar to that of patients with Try-
panosoma cruzi infection (which represents a frequent
cause of chronic heart failure and consequent need for
heart transplant in Latin America) [25]. The similarities
in inflammatory/immune expression patterns between
acute rejection and infection have also been described
by Sarwal et al. [22].
By utilizing an established protein prediction model
for discovering serum biomarkers of disease, (Integrated
RNA Data Driven Proteomics (IRDDP)), Chen et al. [27]
applied this model to cross-organ acute allograft rejec-
tion datasets. In this analysis, three existing gene expres-
sion datasets were analyzed to identify candidate serum
protein biomarkers. Evaluation of the three datasets
revealed 45 genes commonly differentially expressed in
acute allograft rejection (see Table 1). The datasets were
extracted from GEO and were derived from microarray
studies conducted on pediatric renal, adult renal, and
adult cardiac human tissue biopsies during acute allo-
graft rejection. Interestingly, by applying this protein
biomarker prediction model, this data guided the inves-
tigators to discover three serum protein biomarkers,
PECAM1, CXCL9, and CD44, that could distinguish
acute rejection from stable allograft function. Notably,
since gene expression data was compared in heart and
kidney samples, it reinforces the principal that common
molecular mechanisms exist in acute allograft rejection
across different organs.
Another comparative analysis was conducted by Saint-
Mezard et al. [26] analyzing three datasets from human
renal acute allograft rejection microarray studies. These
authors compared their own data, which consisted of
human and non-human primate kidney acute rejection
biopsy specimens, to the Stanford [22] and Cleveland
[23] datasets. By doing so, the authors analyzed 36 acute
rejection samples, identifying 70 genes that were upre-
gulated during acute allograft rejection. Importantly,
they successfully validated their findings by using 143
microarrays from the Edmonton dataset [31].
Using GeneGo MetaCore algorithms (a web-based
suite for functional analysis of experimental data http://
www.genego.com) STAT-1, Interferon Regulatory Factor
(IRF-1), Nuclear Factor Kappa B (NF-kB), and PU.1 (a
transcription factor involved in the in the development
of myeloid and lymphoid cells [188]) were identified as
the main transcription factors that regulate the 70 genes
consistently represented during kidney acute rejection in
according to the Saint-Mezard comparative analysis
[26]. The relationship among different protein-protein
interactions, activation of transcription factors, and
functional response is often difficult to establish because
of its complexity and due to the incompletely under-
stood association among signaling pathways. In simple
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stitutive activation of innate immunity (e.g. TNF-a path-
way), and IRF-1 superimposes a switch toward adaptive
immunity (through the IFN-g pathway). As described
previously, these two pathways can amplify each other,
and can also collaborate in inducing the transcription of
common genes. For example, IFN-g (through IRF-1) and
TNF-a (through NF-kB) can synergize in promoting the
overexpression of common genes such as CXCR3
ligands [67] and CCR5 ligands [144]. Figure 3 sum-
marizes a likely reciprocal enhancement of function
between the NF-kB and the STAT-1/IRF-1 pathways
during allograft rejection. Beyond the function of master
regulator of innate immunity, NF-kB is also important
in driving the adaptive response. In fact, it plays a key
role in IL-2 and TCR signaling, and in the regulation of
immunoglobulin production [152]. It should be noted
that most of the drugs effective in the treatment and/or
prevention of acute allograft rejection (e.g. glucocorti-
coids, cyclosporine, and tacrolimus), interact with NF-
kB pathway, and result in reduced production of several
cytokines such as IL-2 and TNF-a [152]. Accordingly,
NF-kB activity impairment leads to an attenuation of
acute rejection in heart [189-191], lung [192] and skin
[193] in animal models.
Metzincins and Related Genes
Recently, attention has been brought to the role of the
metzincins (a superfamily of endopeptide cleaving extra-
cellular matrix proteins implicated in remodeling and
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Figure 3 Possible mechanism of reciprocal enhancement between innate and adaptive immunity, through NF-kB and STAT-1/IRF-1
pathway. This sketch is built according to genes often described as upregulated during acute allograft rejection in human studies. NF-kB can be
activated by a variety of inflammatory stimuli. For example, the engagement of toll-like receptors (TLRs) by the endogenous danger-associated
molecules may lead to NF-kB activation and transcription of NF-kB induced genes, including TNF-a. TNF-a is a potent activator of NF-kB, thus
forming an amplifying feed-forward loop. Indeed, NF-kB, through inducing transcription of CXCR3 and CCR5 ligands (e.g. CXCL9, -10 and CCL5
respectively), engages Th1 cells, CTLs and NK cells since all express CXCR3 and CCR5. These cells in turn produce IFN-g with consequent
activation of the STAT-1/IRF-1 pathway leading to further production of chemoattractants (CCR5 and CXCR3 ligands) with amplification of the
IFN-g response. IRF-1 can also induce TNF-a production, with further amplification of the loop.
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In the Rodder meta-analysis, expression of Metzincins
and Related Genes (MARGs) were analyzed from four
separate microarray study databases to characterize mar-
kers of acute rejection in renal transplantation
[22,23,29,31], revealing MMP7 and TIMP1 as the most
highly upregulated genes [29]. Interestingly, MMP9,
TIMP1, and ADAM genes have also been noted to be
associated with liver and heart acute allograft rejection
[14,15,25] as listed in Table 1 of this review. Further,
MMP9 and MMP2 were also described to be upregu-
lated in a case report of small bowel acute rejection pro-
filed by microarray. Of note, IFN-g was also upregulated
in this case report emphasizing the similarity cross-
organ in acute allograft rejection [20].
Conclusions
High-throughput gene expression profiling has emerged
as a powerful and reliable tool in investigating immune
response in vivo in humans [11,12]. Bypassing the tradi-
tional hypothesis-driven approach, microarray studies
have revealed unsuspected mechanisms that mediate the
balance between rejection and tolerance.
The pathways thought to be central during acute allo-
graft rejection have been described in this review. Most
of the pathways analyzed (IFN-g/STAT-1/IRF-1 path,
CXCR3/CXCR3 ligands path, CCR5/CCR5 ligands path,
and IEFs path) have also been associated with other
immune-mediated processes, strengthening the concept
that there are common convergent molecular mechan-
isms in tissue specific destruction, as described by the
Immunologic Constant of Rejection [3,194-198]. Even if
the pathways analyzed are consistently observed in
humans, previous experiments in animal models failed
to demonstrate them as necessary or sufficient for the
development of rejection, in concordance with the high
redundancy of mammalian immune system [54,82,83].
Moreover, some of the genes associated with acute
rejection also seem to play a role in tolerance models (e.
g.STAT-1/IRF-1 [159,160]), stressing the pleiotropism of
such molecules, as well as illustrating the complexity of
these networks and the necessity of investigating
immune-response mechanisms in vivo in humans.
Despite the wide-ranging observations at molecular level
which could be significantly influenced by multiple fac-
tors including sample collection time, sample type, sam-
ple handling and storage conditions, patient
physiological condition, coexisting pathological condi-
tions, environmental factors and genetic predisposition,
distinct molecular patterns associated with tissue
destruction have been revealed and summarized in this
review.
In conclusion, the purpose of this review was to con-
tribute to the understanding of how tissue specific
destruction occurs. Understanding why this occurs is
one of the most challenging and intriguing questions
facing modern human immunology.
Additional material
Additional file 1: supplemental data extraction information.
supplemental information for key gene selection used for Table 1, IPA
and Meta Core analysis. Comprehensive lists of relevant upregulated
genes, in according with the original publication, are reported for the
following studies: Akalin et al, Tannapfel et al, Sreekumar et al, Karason et
al (genes most frequently upregulated during the rejection episode and
returned to baseline levels with its resolution), Reeve et al (genes most
frequently represented in the predictive analysis for microarrays classifier),
Saint-Mezard et al. Morgun et al: we reported the upregulated genes
selected from the list of 98 genes belonged to the first predictor set that
discriminate acute cardiac, renal and lung rejection from non rejection.
CCL5 belonged to the second prediction set. Sarwal et al: we selected
key immune genes from the list of genes upregulated in three different
subtypes of acute allograft rejection (see also Mansfield et al. 2004 and
Weintraub et al 2006). Gimino et al and Lande et al: we selected key
genes from a list of genes reported as upregulated during acute
rejection according to the first (Gimino et al) and second (Lande et al)
analyses. Flechner et al: we selected key genes a list of genes
upregulated in acute rejection samples compared to samples without
diagnosis of rejection. Others upregulated genes included in the original
list were: Morgun et al: Homo sapiens cDNA FLJ10266 fis, clone
HEMBB1001024; Homo sapiens cDNA FLJ10580 fis, clone NT2RP2003533,
mRNA sequence; Homo sapiens cDNA FLJ10981 fis, clone PLACE1001610;
Homo sapiens mRNA, cDNA DKFZp434P1019; Homo sapiens mRNA;
cDNA DKFZp564P073; Homo sapiens mRNA; cDNA DKFZp586H0718;
Homo sapiens mRNA; cDNA DKFZp761G0924; Homo sapiens mRNA;
cDNA DKFZp761P221; DKFZP434B033; Unknown (protein for
IMAGE:4251653) [Homo sapiens], mRNA sequence; Unnamed protein
product [Homo sapiens]. Karason: Homo sapiens Alu repeat (LNXI) mRNA
sequence. Reeve et al: affymetrix id 235529_at and 238725_at. The 14
genes selected in the Inkinen et al study were those genes highly
upregulated in AR vs NR control. Morgun et al: we reported the
upregulated genes selected from the list of 98 genes belonged to the
first classifier that discriminate acute cardiac rejection vs non rejection
and immune-related genes selected from the second and third classifier
(130 and 188 genes respectively): the three classifier also discriminated
rejection and non rejection lung and kidney samples. Asaoka et al
analyzed biopsies from 21 liver transplant recipients with recurrent HCV
(RHC). Analysis compared 9 with AR + RHC versus 13 with RHC only
(control). Genes shown in this table selected from the network classified
as “Cell death, hematological disease, and immunological disease” via
IPA.
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